Encell (456070) Fundamentals 2026 — Revenue Analysis | SniperIQ
Encell (456070) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩66.3B, trading at ₩6030.00 on the KOE. This SniperIQ fundamentals page covers Encell's valuation, profitability (net margin -373.7%), revenue (₩5.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Encell's market cap?
Encell (456070) has a market capitalization of approximately ₩66.3B, trading at ₩6030.00 on the KOE. Market cap moves with the live share price.
What is Encell's P/E ratio?
Encell's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Encell?
Encell runs a net profit margin of -373.7%, a gross margin of -55.8%, and an operating margin of -316.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Encell generate?
Encell reported revenue of ₩5.3B for fiscal year 2025, with net income of -₩16.1B and earnings per share (EPS) of -1482. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Encell pay a dividend?
Encell does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Encell financially healthy?
Encell carries a debt-to-equity ratio of 0.36x and a current ratio of 9.07x, with a market beta of 0.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Encell a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Encell (456070) the key facts are: market cap ₩66.3B, revenue ₩5.3B, 52-week range 5780-20950. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Encell's full fundamentals live
Get Encell's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.